This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohn, J. N Search for Related Content PubMed PubMed Citation Articles by Cohn, J. N Pubmed/NCBI databases Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?

Interaction of -blockers and angiotensin receptor blockers/ACE inhibitors in heart failure

Cardiovascular Division Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA, cohnx001{at}umn.edu

The renin-angiotensin-aldosterone system contributes to the progression of heart failure and its inhibition slows ventricular remodelling and favourably affects morbidity and mortality. -blockers exert a remarkably favourable effect on progression that may be mediated at least in part by renin inhibition. Although earlier trials suggested a possible adverse interaction when an angiotensin receptor blocker was added to an angiotensin-converting enzyme inhibitor and a -blocker, a recent study and newly analysed mechanistic data indicate that the triple combination provides modest additional inhibition of angiotensin that can further slow progression of disease.

Key Words: angiotensin • ACE inhibitors • -blockers • morbidity • mortality

References

• CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.[Abstract]
• The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.[Abstract]
• The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685-91.[Abstract]
• Packer M., Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 349-55.[Abstract/Free Full Text]
• Cibis II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Merit-HF Study Group. Effect of metroprolol CR/XL in chronic heart failure: Metroprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-07.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Packer M., Coats AJ, Fowler MB et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect on carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.[Abstract/Free Full Text]
• Cohn JN, Tognoni G., Glazer RD, Spormann D., Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Cardiac Fail 1999;5:155-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pfeffer MA, Swedberg K., Granger CB et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003:362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Granger CB, McMurray JJV, Yusuf S. et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003:362:772-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Packer M., Cohn JN, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(2A):1A-38A.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hunt SA, Baker DW, Chin MH et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001;104:2996-3007.[Free Full Text]
• McDonald KM, Mock J., D'Aloia A. et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8.[Abstract/Free Full Text]
• Cohn JN, Pfeffer MA, Rouleau J. et al., for the MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail, in press.
• Campbell DJ, Aggarwal A., Esler M., Kaye D. β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001;358:1609-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• McMurray JJV, Östergren J., Swedberg K. et al., for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003:362:767-71.1.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wong M., Staszewsky L., Latini R. et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002;4:970-5.
• Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;11:1278-83.
• Jorde, UP, Ennezat PV, Lisker J. et al. Maximally recommended doses of angiotensin converting enzyme (ACE) inhibitors do not completely prevent ACE-medicated formation of angiotensin II in chronic heart failure. Circulation 2000; 101:844-6.[Abstract/Free Full Text]
• Packer M., Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-18.[Abstract/Free Full Text]
• Carson P., Krum H., Cohn JN, on behalf of the Val-HeFT Investigators. The effect of baseline ACE inhibitor dose on the efficacy of valsartan in Val-HeFT. (Abstract). Circulation 2002:II-511.
• Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
• Pitt B., Remme W., Zannad F. et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 4, No. 3, 137-139 (2003)
DOI: 10.3317/jraas.2003.021


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? Circulation, November 16, 2004; 110(20): 3281 - 3288. [Full Text] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohn, J. N Search for Related Content PubMed PubMed Citation Articles by Cohn, J. N Pubmed/NCBI databases Medline Plus Health Information Heart Failure Social Bookmarking                         What's this?